Immunotoxins, formulations thereof and their use in medicine
AssigneePhilikos B.V.
InventorsHenricus Gerardus VAN HOOREN, Maarten Jaap Frijlink, Ypke Vincentius Johannes Maria Van Oosterhout
Life of this patent
Estimating the term…
Abstract
The present invention provides a composition comprising a first antibody molecule that specifically recognizes CD3 and a second antibody molecule that specifically recognizes CD7, for use in a method of treatment, or preventative treatment of viral infection or viral reactivation in a mammalian subject undergoing immunomodulatory treatment, wherein the first and second antibody molecules are each provided with a toxic moiety. Also provided is a method of treating a mammalian subject having, or being at risk of developing, chronic Graft versus Host disease (cGVHD). Also provided is a related pharmaceutical composition.
Claims18
-22. (canceled)
A method of treating a mammalian subject having, or being at risk of, a viral infection or viral reactivation, the method comprising:
- administering, simultaneously, separately or sequentially, a therapeutically effective amount of a first antibody molecule that specifically recognises CD3 and a second antibody molecule that specifically recognises CD7, wherein the first and second antibody molecules are each provided with a toxic moiety, to the subject in need of said treatment, and wherein the subject is undergoing immunomodulatory treatment.
-45. (canceled)
A composition comprising a first antibody molecule that specifically recognises CD3 and a second antibody molecule that specifically recognises CD7, for use in a method of treatment, or prcventative treatment, of chronic Graft versus Host disease (cGVHD) in a mammalian subject undergoing immunomodulatory treatment, wherein the first and second antibody molecules are each provided with a toxic moiety.
-55. (canceled)
A pharmaceutical composition comprising:
- (i) 0.05 to 0.5 mg/mL, optionally 0.2 mg/mL, of a monoclonal antibody molecule that specifically recognises CD3 and which is conjugated to at least one ricin toxin A (RTA), and/or
- 0.05 to 0.5 mg/mL, optionally 0.2 mg/mL, of a monoclonal antibody molecule that specifically recognises CD7 and which is conjugated to at least one RTA;
- (ii) 5 to 20 mM, optionally 10 mM, of a citrate buffer;
- (iii) 50 to 300 mM, optionally 75 to 200 mM or 125 mM, of L-arginine or a pharmaceutically acceptable salt thereof;
- (vi) 0.01 to 0.1% (w/v), optionally 0.05% (w/v), of a polysorbate,
- wherein the composition is in water and has a pH in the range 6 to 7.5, optionally 6.5.
64-71. (canceled)
Dependencies are inferred from the claim text.